Management of the behavioural and psychological symptoms of dementia remains a challenge worldwide. Herbal medicines may play a role in the development of new interventions. To determine effects of herbal medicines for management of the behavioural and psychological symptoms of dementia, meta-analysis was conducted of 31 controlled trials (3613 participants). Frequently tested herbal medicines were the Ginkgo biloba leaf extract EGb 761 (seven studies) and the multi-ingredient formula Yokukansan (eight studies). Sixteen studies tested other herbal medicines. Improvements were detected in Neuropsychiatric Inventory scores in EGb 761 groups compared to placebo (MD −3.46 [−5.94, −0.98]; I2 = 93%; n = 1757) and Yokukansan groups compared to no treatment (SMD −0.53 [−0.86, −0.21]; I2 = 0%; n = 150). Cognitive scores were improved in EGb 761 groups while Yokukansan did not appear to affect cognitive function. Of the other herbal medicines, there were improvements in the behavioural and psychological symptoms of dementia and cognitive outcomes in two of four placebo-controlled studies. EGb 761 and Yokukansan appeared safe and well tolerated. Adverse effects and dropouts were not reported consistently for the other herbal medicines. Weaknesses of these included short durations, small sample sizes, lack of blinding and other risks of bias. Well-designed studies are needed to further investigate the reported effects of these interventions on the behavioural and psychological symptoms of dementia.
AntonsdottirIMSmithJKeltzM. (2015) Advancements in the treatment of agitation in Alzheimer’s disease. Expert Opin Pharmacother16: 1649–1656.
2.
ApetzNMunchGGovindaraghavanS. (2014) Natural compounds and plant extracts as therapeutics against chronic inflammation in Alzheimer’s disease – a translational perspective. CNS Neurol Disord: Drug Targets13: 1175–1191.
3.
AraiYCKawanishiJSakakimaY. (2014) The effect of the kampo medicine yokukansan on preoperative anxiety and sedation levels. Evidence-Based Complementary Altern Med2014: 965045.
4.
BallardCSmithJHuseboB. (2011) The role of pain treatment in managing the behavioural and psychological symptoms of dementia (BPSD). Int J Palliative Nurs17: 420, 422, 424.
5.
BarkerMJGreenwoodKMJacksonM. (2004) Cognitive effects of long-term benzodiazepine use: a meta-analysis. CNS Drugs18: 37–48.
6.
BenskyDClaveySGambleA. (2004) Chinese herbal medicine: materia medica. Seattle: Eastland Press, Inc.
7.
BiMTongSZhangZ. (2011) Changes in cerebral glucose metabolism in patients with mild-to-moderate Alzheimer’s disease: a pilot study with the Chinese herbal medicine fuzhisan. Neurosci Lett501: 35–40.
8.
BirksJGrimley EvansJ (2009) Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev (1): Cd003120.
9.
BrondinoNDe SilvestriAReS. (2013) A Systematic Review and Meta-Analysis of Ginkgo biloba in Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day Medicine. Evidence-Based Complementary Altern Med2013: 915691.
10.
BrondinoNReSBoldriniA. (2014) Curcumin as a therapeutic agent in dementia: a mini systematic review of human studies. Sci World J2014: 174282.
11.
BrownRHowardRCandyB. (2015) Opioids for agitation in dementia. Cochrane Database Syst Rev5: Cd009705.
12.
Carhart-HarrisRLBolstridgeMRuckerJ. (2016) Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry3: 619–627.
13.
CerejeiraJLagartoLMukaetova-LadinskaEB (2012) Behavioral and psychological symptoms of dementia. Front Neurol3: 73.
14.
ChenTGaoM (2013) Clinical observation of treatment of herbal granules on behavioural and psychological symptoms of dementia [in Chinese] [脑灵颗粒治疗痴呆行为精神症状的临床观察]. Yunnan J Tradit Med [Yunnan Zhongyi Zhongyao Zazhi]34: 33–34.
15.
ChengXWZangD (2013) Yang xue qing nao ke li combined with donepezil for cognition in Alzheimer’s disease patients with functional, cognitive and behavioural abnormalities [in Chinese] [养血清脑颗粒联合多奈哌齐对AD 患者认知功能及精神行为学异常的影响]. Shandong Med J [Shandong Yiyao]53: 56–57.
16.
CheungGStapelbergJ (2011) Quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD): a meta-analysis of randomised placebo-controlled trials. N Z Med J124(1336): 39–50.
17.
CheungTSSongTHNgTB. (2015) Therapeutic Effects of Herbal Chemicals in Traditional Chinese Medicine on Alzheimer’s Disease. Curr Med Chem22: 2392–2403.
18.
CoxKHPipingasAScholeyAB (2015) Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. J Psychopharmacol29: 642–651.
19.
CumboELigoriLD (2014) Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer’s disease: a 12-month, randomized, open-label trial. J Alzheimer’s Dis39: 477–485.
20.
CummingsJEmreMAarslandD. (2010) Effects of rivastigmine in Alzheimer’s disease patients with and without hallucinations. J Alzheimer’s Dis20: 301–311.
21.
CummingsJL (1997) The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology48(5 Suppl 6): S10–16.
22.
CummingsJLIhlRHerrschaftH. (2013) Sensitivity to change of composite and frequency scores of the Neuropsychiatric Inventory in mild to moderate dementia. Int Psychogeriatr25: 431–438.
23.
CummingsJLMegaMGrayK. (1994) The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology44: 2308–2314.
24.
DonaldsonCTarrierNBurnsA (1998) Determinants of carer stress in Alzheimer’s disease. Int J Geriatr Psychiatry13: 248–256.
25.
DongLMayBHFengM. (2016) Chinese Herbal Medicine for Mild Cognitive Impairment: A Systematic Review and Meta-Analysis of Cognitive Outcomes. Phytother Res30: 1592–1604.
26.
Dos Santos-NetoLLde Vilhena ToledoMAMedeiros-SouzaP. (2006) The use of herbal medicine in Alzheimer’s disease-a systematic review. Evidence-Based Complementary Altern Med3: 441–445.
27.
ErkinjunttiTGauthierSBullockR. (2008) Galantamine treatment in Alzheimer’s disease with cerebrovascular disease: responder analyses from a randomized, controlled trial (GAL-INT-6). J Psychopharmacol22: 761–768.
28.
ErzigkeitH (1989) The SKT: a short cognitive performance test as an instrument for the assessment of clinical efficacy of cognitive enhancers. In: BergenerMReisbergB (eds) Diagnosis and treatment of senile dementia. Berlin: Springer, pp. 164–174.
29.
FolsteinMFFolsteinSEMcHughPR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12: 189–198.
30.
FuLMLiJT (2011) A systematic review of single Chinese herbs for Alzheimer’s disease treatment. Evidence-Based Complementary Altern Med2011: 640284.
31.
FungJKTsangHWChungRC (2012) A systematic review of the use of aromatherapy in treatment of behavioral problems in dementia. Geriatr Gerontol Int12: 372–382.
32.
FuruhashiYShinK (2011) Risperidone Versus Yokukansan in the Treatment of Severe Alzheimer’s Disease. Int J Clin Med2: 166–170.
33.
FurukawaKTomitaNUematsuD. (2015) Randomized double-blind placebo-controlled multicenter trial of Yokukansan for neuropsychiatric symptoms in Alzheimer’s disease. Geriatr Gerontol Int. DOI: 10.1111/ggi.12696
34.
GauthierSSchlaefkeS (2014) Efficacy and tolerability of Ginkgo biloba extract EGb 761(R) in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin Interventions Aging9: 2065–2077.
35.
GavrilovaSIPreussUWWongJW. (2014) Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial. Int J Geriatr Psychiatry29: 1087–1095.
36.
GentileS (2010) Second-generation antipsychotics in dementia: beyond safety concerns. A clinical, systematic review of efficacy data from randomised controlled trials. Psychopharmacology212: 119–129.
37.
GotoHFujimotoMWatanabeT. (2010) Trial of the Treatment of Kampo Medicines for Thalamic Pain. Kampo Med61: 189–197.
38.
Guideline Adaptation Committee (2016) Clinical Practice Guidelines and Principles of Care for People with Dementia. Sydney: NHMRC Partnership Centre for Dealing with Cognitive and Related Functional Decline in Older People.
39.
GuoZChenXLinB (2011) Zhi bai di huang tang combined with donepezil for treatment of senile dementia associated with 30 cases of abnormal behaviour [in Chinese] [知柏地黄汤联合多奈哌齐治疗老年性痴呆伴发精神行为异常30例]Zhejiang Med [Zhejiang Zhong Xiyi Jiehe Zazhi]21: 471–472.
40.
GuoZChenXXingB (2013) Clinical study of reinhardt and sea cucumber capsule combined with donepezil in treatment of psychological and behavioral symptoms in patients with Alzheimer’s disease [in Chinese] [补肾化痰方联合盐酸多奈哌齐对中重度阿尔茨海默病伴精神行为症状的临床研究]. [Zhejiang Med College] [Zhejiang Yixue]35: 2089–2092.
41.
Hamazaki-FujitaNYoshidaMYomodaS. (2013) Effects of Yokukansankachimpihange on cognitive ability, an open randomized controlled trial [in Japanese] [ランダム化比較オープ開ン試験 による抑肝散加陳皮半夏の認知機能に開する 臨床試]. Psychiatry23: 130–138.
42.
HaoWYeFLiL (2006) Clinical observations of Tongxingluo capsule in the treatment of vascular dementia [in Chinese] [通心络胶囊 治疗 血管性痴呆患者临床观察]. J Clin Psychomatic Dis [Linchuang Xinshen Jibing Zazhi]12: 424–425.
43.
HelmstadterAStaigerC (2014) Traditional use of medicinal agents: a valid source of evidence. Drug Discovery Today19: 4–7.
44.
HeoJHLeeSTChuK. (2008) An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer’s disease. Eur J Neurol15: 865–868.
45.
HeoJHLeeSTChuK. (2012) Heat-processed ginseng enhances the cognitive function in patients with moderately severe Alzheimer’s disease. Nutr Neurosci15: 278–282.
46.
HeoJHLeeSTOhMJ. (2011) Improvement of cognitive deficit in Alzheimer’s disease patients by long term treatment with Korean red ginseng. J Ginseng Res35: 457–461.
47.
HerrschaftHNacuALikhachevS. (2012) Ginkgo biloba extract EGb 761(R) in dementia with neuropsychiatric features: a randomised, placebo-controlled trial to confirm the efficacy and safety of a daily dose of 240 mg. J Psychiatr Res46: 716–723.
48.
HigginsJPTGreenS (2011) Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration. www.handbook.cochrane.org
49.
HoerrRWeberW (2015) Ginkgo biloba and Usage in Dementia: From Eastern Tradition to Western Science. In: MartinCPPreedyV (eds) Diet and Nutrition in Dementia and Cognitive Decline. London: Elsevier, pp. 1021–1030.
50.
HuXJYuCJLiJ. (2015) Clinical Analysis of Bushen Tongluo Decoction in Treating 40 Patients with Alzheimer’s Disease [in Chinese]. [补肾通络汤治疗阿尔茨海默病40 例的临床分析]Chin J Exp Tradit Med Formulae [Zhongguo Shiyan Fangjixue Zazhi]21: 182–185.
51.
HuYLiuPGuoDH. (2010) Antidepressant effects of the extract YZ-50 from Polygala tenuifolia in chronic mild stress treated rats and its possible mechanisms. Pharm Biol48: 794–800.
52.
HugelHJacksonN (2015) Nutraceuticals and Dietary Components in Dementia and Cognitive Decline. In: MartinCPPreedyV (eds) Diet and Nutrition in Dementia and Cognitive Decline. London: Elsevier, pp. 795–804.
53.
HuseboBSBallardCSandvikR. (2011) Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ (Clin Res Ed.)343: d4065.
54.
IhlR (2013) Effects of Ginkgo biloba extract EGb 761 (R) in dementia with neuropsychiatric features: review of recently completed randomised, controlled trials. Int J Psychiatry Clin Pract17Suppl 1: 8–14.
55.
IhlRBachinskayaNKorczynAD. (2011) Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. Int J Geriatr Psychiatry26: 1186–1194.
56.
IhlRTribanekMBachinskayaN (2010) Baseline neuropsychiatric symptoms are effect modifiers in Ginkgo biloba extract (EGb 761(R)) treatment of dementia with neuropsychiatric features. Retrospective data analyses of a randomized controlled trial. J Neurol Sci299: 184–187.
57.
IkarashiYMizoguchiK (2016) Neuropharmacological efficacy of the traditional Japanese Kampo medicine yokukansan and its active ingredients. Pharmacol Ther166: 84–95.
58.
IwasakiKSatoh-NakagawaTMaruyamaM. (2005) A randomized, observer-blind, controlled trial of the traditional Chinese medicine Yi-Gan San for improvement of behavioral and psychological symptoms and activities of daily living in dementia patients. J Clin Psychiatry66: 248–252.
59.
JiangLSuLCuiH. (2013) Ginkgo biloba extract for dementia: a systematic review. Shanghai Arch Psychiatry25(1): 10–21.
60.
KasperS (2015) Phytopharmaceutical treatment of anxiety, depression, and dementia in the elderly: evidence from randomized, controlled clinical trials. Wien Med Wochenschr165: 217–228.
61.
KauferDICummingsJLKetchelP. (2000) Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory. J Neuropsychiatry Clin Neurosci12: 233–239.
62.
KishidaY (2014) The efficacy of Kampo medicine for the diseases and joint pain [in Japanese] [Kotsukansetsu shikkan ni taisuru kanpōyaku no rieki-sei kōka]. Folia Pharmacol Jpn [Nihon Yakurigaku Zasshi]143: 69–72.
63.
KudohCAritaRHondaM. (2015) Effect of ninjin’yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer’s disease: 2 years of observation. Psychogeriatrics16: 85–92.
64.
LangFHoerrRNoeldnerMKochE (2013). Ginkgo biloba extract EGb 761: from an ancient Asian plant to a modern European herbal medicinal product. In: WagnerHUlrich-MerzenichG (eds). Evidence and rational based research on Chinese drugs. Vienna:Springer Vienna, pp. 431–470.
65.
LeeSHJungBHKimSY. (2006) The antistress effect of ginseng total saponin and ginsenoside Rg3 and Rb1 evaluated by brain polyamine level under immobilization stress. Pharmacol Res54: 46–49.
LiXCuiJYuY. (2016) Traditional Chinese Nootropic Medicine Radix Polygalae and Its Active Constituent Onjisaponin B Reduce beta-Amyloid Production and Improve Cognitive Impairments. PLoS One11: e0151147.
LockhartIAOrmeMEMitchellSA (2011) The efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer’s disease: systematic review and meta-analysis. Dementia Geriatr Cognit Disord Extra1: 212–227.
70.
LooiJCMacfarlaneS (2014) Psychotropic drug use in aged care facilities: a reflection of a systemic problem?Med J Aust200: 13–14.
71.
LovheimHSandmanPOKarlssonS. (2008) Behavioral and psychological symptoms of dementia in relation to level of cognitive impairment. Int Psychogeriatr20: 777–789.
72.
LoyCSchneiderL (2006) Galantamine for Alzheimer’s disease and mild cognitive impairment. Cochrane Database Syst Rev (1): Cd001747.
73.
LyketsosCGSteinbergMTschanzJT. (2000) Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry157: 708–714.
74.
McClamTDMaranoCMRosenbergPB. (2015) Interventions for Neuropsychiatric Symptoms in Neurocognitive Impairment Due to Alzheimer’s Disease: A Review of the Literature. Harv Rev Psychiatry23: 377–393.
75.
MagierskiRSobowT (2016) Serotonergic drugs for the treatment of neuropsychiatric symptoms in dementia. Expert Rev Neurother16: 375–387.
76.
MaidmentIDFoxCGBoustaniM. (2008) Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis. Ann Pharmacother42: 32–38.
77.
Martinon-TorresGFioravantiMGrimleyEJ (2004) Trazodone for agitation in dementia. Cochrane Database Syst Rev (4): Cd004990.
78.
MatsudaYKishiTShibayamaH. (2013) Yokukansan in the treatment of behavioral and psychological symptoms of dementia: a systematic review and meta-analysis of randomized controlled trials. Hum Psychopharmacol28: 80–86.
79.
MatsumotoKZhaoQNiuY. (2013) Kampo formulations, chotosan, and yokukansan, for dementia therapy: existing clinical and preclinical evidence. J Pharmacol Sci122: 257–269.
80.
MatsunagaSKishiTIwataN (2016) Yokukansan in the Treatment of Behavioral and Psychological Symptoms of Dementia: An Updated Meta-Analysis of Randomized Controlled Trials. J Alzheimer’s Dis54: 635–643.
81.
MattioliLFunariCPerfumiM (2009) Effects of Rhodiola rosea L. extract on behavioural and physiological alterations induced by chronic mild stress in female rats. J Psychopharmacol23: 130–142.
82.
MaurerKIhlRDierksT. (1997) Clinical efficacy of Ginkgo biloba special extract EGb 761 in dementia of the Alzheimer type. J Psychiatr Res31: 645–655.
83.
MaustDTKimHMSeyfriedLS. (2015) Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry72: 438–445.
84.
MayBHLitMXueCC. (2009a) Herbal medicine for dementia: a systematic review. Phytother Res23: 447–459.
85.
MayBHLuCBennettL. (2012) Evaluating the traditional Chinese literature for herbal formulae and individual herbs used for age-related dementia and memory impairment. Biogerontology13: 299–312.
86.
MayBHYangAWZhangAL. (2009b) Chinese herbal medicine for Mild Cognitive Impairment and Age Associated Memory Impairment: a review of randomised controlled trials. Biogerontology10: 109–123.
87.
MayBHZhangALRobinsonSR. (2015) Chinese herbs for cognitive decline: historical and contemporary applications. In: MartinCPPreedyV (eds) Diet and Nutrition in Dementia and Cognitive Decline. London: Elsevier, pp. 805–818.
88.
MiaoFRuanjiaA (2009) Bu shen hua tan decoction on 59 cases of vascular dementia [in Chinese] [补肾化痰汤治疗血管性痴呆59例]J Shaanxi Coll Tradit Chin Med [Shaanxi Zhongyi Xueyuan Xuebao]32: 30.
89.
MiyaokaTFuruyaMHoriguchiJ. (2014) Efficacy and safety of yokukansan in treatment-resistant schizophrenia: a randomized, double-blind, placebo-controlled trial (a Positive and Negative Syndrome Scale, five-factor analysis). Psychopharmacology (Berlin)232: 155–164.
90.
MizukamiK (2014) Kampo therapy and behavioural and psychological symptoms of dementia. Tradit Kampo Med1: 11–18.
91.
MizukamiKAsadaTKinoshitaT. (2009) A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in the treatment of the behavioural and psychological symptoms of dementia. Int J Neuropsychopharmacol12: 191–199.
92.
MohsRCRosenWGDavisKL (1983) The Alzheimer’s disease assessment scale: an instrument for assessing treatment efficacy. Psychopharmacol Bull19: 448–450.
93.
MonjiATakitaMSamejimaT. (2009) Effect of yokukansan on the behavioral and psychological symptoms of dementia in elderly patients with Alzheimer’s disease. Prog Neuro-Psychopharmacol Biol Psychiatry33: 308–311.
94.
NacuAHoerrR (2016) Neuropsychiatric symptoms in dementia and the effects of Ginkgo biloba extract EGb 761(R) treatment: additional results from a 24-week randomized, placebo-controlled trial. Open Access J Clin Trials8: 1–6.
95.
NakamuraYTajimaKKawagoeI. (2009) Efficacy of traditional herbal medicine, Yokukansan on patients with neuropathic pain [in Japanese] [伝統的な漢方薬の有効性、抑肝散神経因性疼痛を有する患者に]. Jpn J Anesthesiol [Masui]58: 1248–1255.
96.
NapryeyenkoOBorzenkoI (2007) Ginkgo biloba special extract in dementia with neuropsychiatric features. A randomised, placebo-controlled, double-blind clinical trial. Arzneim Forsch57: 4–11.
97.
NapryeyenkoOIhlRSchlaefkeS. (2005) Ginkgo biloba Extract EGb 761 (R) in the Treatment of Dementia with Neuropsychiatric Features: A Randomized, Placebo-controlled, Double-blind Trial. Poster presented at: 21st International Conference of Alzheimer’s Disease International. September 2005, Istanbul, Turkey.
98.
National Institute for Health and Clinical Excellence (NICE) (2007, updated in 2014) A NICE-SCIE Guideline on Supporting People with Dementia and their Carers in Health and Social Care. London: The British Psychological Society and Gaskell.
99.
NewmanDJCraggGM (2016) Natural Products as Sources of New Drugs from 1981 to 2014. J Nat Prod79: 629–661.
100.
NikolovaGYanchevaSRaychevI. (2013) Ginkgo biloba extract in dementia: A 22-week randomised, placebo-controlled, double-blind trial [in Bulgarian] [екстракт Ginkgo biloba билоба в деменция: А 22-седмично рандомизирано, плацебо-контролирано, двойно-сляпо проучване. Bulg Neurol [Bŭlgarska nevrologiya]14: 139–143.
101.
OkaharaKIshidaYHayashiY. (2010) Effects of Yokukansan on behavioral and psychological symptoms of dementia in regular treatment for Alzheimer’s disease. Prog Neuro-Psychopharmacol Biol Psychiatry34: 532–536.
102.
PanWWangQKwakS. (2014) Shen-zhi-ling oral liquid improves behavioral and psychological symptoms of dementia in Alzheimer’s disease. Evidence-Based Complementary Altern Med2014: 913687.
103.
PosadzkiPWatsonLKErnstE (2013) Adverse effects of herbal medicines: an overview of systematic reviews. Clin Med13: 7–12.
104.
Press-SandlerOFreudTVolkovI. (2016) Aromatherapy for the Treatment of Patients with Behavioral and Psychological Symptoms of Dementia: A Descriptive Analysis of RCTs. J Altern Complementary Med22: 422–428.
105.
PuZPFeiYLinY. (2014) Treatment of Vascular Dementia Patients with Agitation of Blood Stagnation Syndrome by Oxcarbazepine And Tongqiaohuoxue Decoction Separately: An Efficacy Comparison [in Chinese][奥卡西平与通窍活血汤治疗瘀血内阻型血管性痴呆患者激越行为疗效比较]. Zhejiang Med [Zhejiang Zhong Xiyi Jiehe Zazhi]24: 659–661; 668.
106.
RafiiMSWalshSLittleJT. (2011) A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology76: 1389–1394.
107.
ReisbergBBorensteinJSalobSP. (1987) Behavioral symptoms in Alzheimer’s disease: phenomenology and treatment. J Clin Psychiatry48(Supplementary): 9–15.
108.
RingmanJMFrautschySATengE. (2012) Oral curcumin for Alzheimer’s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimer’s Res Ther4: 43.
109.
RosenWGMohsRCDavisKL (1984) A new rating scale for Alzheimer’s disease. Am J Psychiatry141: 1356–1364.
110.
SchneiderLSDeKoskySTFarlowMR. (2005) A randomized, double-blind, placebo-controlled trial of two doses of Ginkgo biloba extract in dementia of the Alzheimer’s type. Curr Alzheimer Res2: 541–551.
111.
SchneiderLSTariotPNDagermanKS. (2006) Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. N Engl J Med355: 1525–1538.
112.
SeitzDPAdunuriNGillSS. (2011) Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev (2): Cd008191.
113.
ShaoHMiZJiWG. (2015) Rhynchophylline Protects Against the Amyloid beta-Induced Increase of Spontaneous Discharges in the Hippocampal CA1 Region of Rats. Neurochem Res40: 2365–2373.
114.
ShelefABarakYBergerU. (2016) Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study. J Alzheimer’s Dis51: 15–19.
115.
ShibaharaNKuwaharaYKatohM. (1992) A trial of Kampoh therapy for pain and numbness associated with cerebro-vascular disorders [in Japanese] [脳血管障害後遺症に伴う痛み・しびれ感に対する和漢薬治療の試み]. Jpn J Orient Med [Nihon Tōyō Igaku Zasshi]43: 27–36.
116.
SuYWangQWangC. (2014) The treatment of Alzheimer’s disease using Chinese medicinal plants: from disease models to potential clinical applications. J Ethnopharmacol152: 403–423.
117.
TakedaAIwakiHIdeK. (2012) Therapeutic effect of Yokukansan on social isolation-induced aggressive behavior of zinc-deficient and pair-fed mice. Brain Res Bull87: 551–555.
118.
TanMSYuJTTanCC. (2015) Efficacy and adverse effects of ginkgo biloba for cognitive impairment and dementia: a systematic review and meta-analysis. J Alzheimer’s Dis43: 589–603.
119.
TanakaYSakiyamaT (2013) Potential usefulness of the kampo medicine yokukansan, containing uncaria hook, for paediatric emotional and behavioural disorders: a case series. Evidence-Based Complementary Altern Med2013: 502726.
120.
TangCYeYFengY. (2016) TCM, brain function and drug space. Nat Prod Rep33: 6–25.
121.
TeranishiMKuritaMNishinoS. (2013) Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial. J Clin Psychopharmacol33: 600–607.
122.
TerawakiKIkarashiYSekiguchiK. (2010) Partial agonistic effect of yokukansan on human recombinant serotonin 1A receptors expressed in the membranes of Chinese hamster ovary cells. J Ethnopharmacol127: 306–312.
123.
TsuboTNishimuraMSaitoJ. (2012) The experience of the use of yokukansan as sedatives in ICU. J Jpn Soc Intensive Care Med19: 83–84.
124.
UedaTUgawaSIshidaY. (2011) Geissoschizine methyl ether has third-generation antipsychotic-like actions at the dopamine and serotonin receptors. Eur J Pharmacol671: 79–86.
125.
UekiTNishiAImamuraS. (2013) Effects of geissoschizine methyl ether, an indole alkaloid in Uncaria hook, a constituent of yokukansan, on human recombinant serotonin 7 receptor. Cell Mol Neurobiol33: 129–135.
126.
VaingankarJAChongSAAbdinE. (2015) Care participation and burden among informal caregivers of older adults with care needs and associations with dementia. Int Psychogeriatr28: 221–231.
127.
Van Dalen-KokAHPieperMJde WaalMW. (2015) Association between pain, neuropsychiatric symptoms, and physical function in dementia: a systematic review and meta-analysis. BMC Geriatr15: 49.
128.
Van den ElsenGAAhmedAIVerkesRJ. (2015) Tetrahydrocannabinol in Behavioral Disturbances in Dementia: A Crossover Randomized Controlled Trial. Am J Geriatr Psychiatry23: 1214–1224.
129.
VigenCLMackWJKeefeRS. (2011) Cognitive effects of atypical antipsychotic medications in patients with Alzheimer’s disease: outcomes from CATIE-AD. Am J Psychiatry168: 831–839.
130.
WakeRMiyaokaTInagakiT. (2013) Yokukansan (TJ-54) for irritability associated with pervasive developmental disorder in children and adolescents: a 12-week prospective, open-label study. J Child Adolesc Psychopharmacol23: 329–336.
131.
WangYYangGGongJ. (2016) Ginseng for Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Curr Top Med Chem16: 529–536.
132.
WeberKMeiler-MititeluCHerrmannFR. (2009) Longitudinal assessment of psychotherapeutic day hospital treatment for neuropsychiatric symptoms in dementia. Aging Mental Health13: 92–98.
133.
WeinmannSRollSSchwarzbachC. (2010) Effects of Ginkgo biloba in dementia: systematic review and meta-analysis. BMC Geriatr10: 14.
134.
WeintraubDRosenbergPBDryeLT. (2010) Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes. Am J Geriatr Psychiatry18: 332–340.
135.
YanchevaSIhlRNikolovaG. (2009) Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer’s disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging Mental Health13: 183–190.
136.
YangGWangYSunJ. (2016) Ginkgo Biloba for Mild Cognitive Impairment and Alzheimer’s Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Curr Top Med Chem16: 520–528.
137.
YaoYJiaMWuJG. (2010) Anxiolytic and sedative-hypnotic activities of polygalasaponins from Polygala tenuifolia in mice. Pharm Biol48: 801–807.
138.
ZengLZouYKongL. (2015) Can Chinese Herbal Medicine Adjunctive Therapy Improve Outcomes of Senile Vascular Dementia? Systematic Review with Meta-analysis of Clinical Trials. Phytother Res29: 1843–1857.
139.
ZhangLFialaMCashmanJ. (2006) Curcuminoids enhance amyloid-beta uptake by macrophages of Alzheimer’s disease patients. J Alzheimer’s Dis10: 1–7.
140.
ZhangYLinCZhangL. (2015) Cognitive Improvement during Treatment for Mild Alzheimer’s Disease with a Chinese Herbal Formula: A Randomized Controlled Trial. PLoS One10: e0130353.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
